Drugs / Carboxyamidotriazole Orotate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01954030 | Oct 2013 → Jul 2015 | malignant glioma | Annick Desjardins | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01107522 | May 2010 → Jan 2025 | glioblastoma | Tactical Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carboxyamidotriazole Orotate | “Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.” PMID 29683790 ↗ Apr 20181“Carboxyamidotriazole Orotate (CTO)” NCT01954030 ↗ |
| Known as | CTO | “Purpose Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non-voltage-dependent calcium channels with modulatory effects in multiple cell-signaling pathways and...” PMID 29683790 ↗ Apr 2018 |
| Action | Inhibit | “Carboxyamidotriazole orotate (CTO) is a novel oral inhibitor of non-voltage-dependent calcium channels” PMID 29683790 ↗ Apr 2018 |
| Route | Oral | “Oral administration daily for 28 day cycles” NCT01107522 ↗ |